JP7383285B2 - 肺高血圧症の治療及び予防における２－ヒドロキシベンジルアミンの使用 - Google Patents

肺高血圧症の治療及び予防における２－ヒドロキシベンジルアミンの使用 Download PDF

Info

Publication number
JP7383285B2
JP7383285B2 JP2019526008A JP2019526008A JP7383285B2 JP 7383285 B2 JP7383285 B2 JP 7383285B2 JP 2019526008 A JP2019526008 A JP 2019526008A JP 2019526008 A JP2019526008 A JP 2019526008A JP 7383285 B2 JP7383285 B2 JP 7383285B2
Authority
JP
Japan
Prior art keywords
bmpr2
substituted
glutamine
pharmaceutically acceptable
unsubstituted alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019526008A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019536778A (ja
JP2019536778A5 (enExample
Inventor
フェッセル，ジョシュア，ピー．
ロバーツ，エル．，ジャクソン
ウエスト，ジェームズ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vanderbilt University
Original Assignee
Vanderbilt University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanderbilt University filed Critical Vanderbilt University
Publication of JP2019536778A publication Critical patent/JP2019536778A/ja
Publication of JP2019536778A5 publication Critical patent/JP2019536778A5/ja
Application granted granted Critical
Publication of JP7383285B2 publication Critical patent/JP7383285B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2019526008A 2016-11-15 2017-11-15 肺高血圧症の治療及び予防における２－ヒドロキシベンジルアミンの使用 Active JP7383285B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662422486P 2016-11-15 2016-11-15
US62/422,486 2016-11-15
PCT/US2017/061854 WO2018093936A1 (en) 2016-11-15 2017-11-15 Use of 2-hydroxybenzylamine in the treatment and prevention of pulmonary hypertension

Publications (3)

Publication Number Publication Date
JP2019536778A JP2019536778A (ja) 2019-12-19
JP2019536778A5 JP2019536778A5 (enExample) 2020-12-24
JP7383285B2 true JP7383285B2 (ja) 2023-11-20

Family

ID=62145792

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019526008A Active JP7383285B2 (ja) 2016-11-15 2017-11-15 肺高血圧症の治療及び予防における２－ヒドロキシベンジルアミンの使用

Country Status (9)

Country Link
US (2) US20190314302A1 (enExample)
EP (2) EP3541185B1 (enExample)
JP (1) JP7383285B2 (enExample)
CN (1) CN110177463B (enExample)
AU (1) AU2017362328B2 (enExample)
ES (1) ES2981715T3 (enExample)
HU (1) HUE067036T2 (enExample)
PL (1) PL3541185T3 (enExample)
WO (1) WO2018093936A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11400103B2 (en) * 2015-12-21 2022-08-02 Vanderbilt University Methods of preventing platelet activation
US20220162240A1 (en) 2019-01-25 2022-05-26 Vanderbilt University Mitochondria-targeted isoketal/isolevuglandin scavengers
EP4097115A4 (en) * 2020-01-27 2024-03-13 Vanderbilt University ANTI-MITOCHONDRIAL ISOKETAL/ISOLEVUGLANDIN SCAVENGERS AND USES THEREOF
JP2023545304A (ja) * 2020-10-13 2023-10-27 ヴァンダービルト ユニバーシティー 腎傷害による腸リンパ管の乱れを予防する方法

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006521349A (ja) 2003-03-27 2006-09-21 メディキュア インコーポレーテッド 狭心症を治療するための組成物
US20100017971A1 (en) 2006-09-01 2010-01-28 Kao Corporation One-part hair dye composition
US20100172971A1 (en) 2006-11-13 2010-07-08 Mccarty Mark Fredrick Compositions for Inhibiting NADPH Oxidase Activity
US20120015501A1 (en) 2010-07-14 2012-01-19 Chang-Ching Tu Silicon Surface Modification for the Electrochemical Synthesis of Silicon Particles in Suspension
US20120157501A1 (en) 2004-10-20 2012-06-21 Vanderbilt University Isoketal scavengers and mitigation of disorders involving oxidative injury
JP2014524918A (ja) 2011-07-12 2014-09-25 ヴァンダービルト ユニバーシティー ガンマ−ケトアルデヒド捕捉剤による炎症および高血圧の治療方法
WO2015127163A1 (en) 2014-02-20 2015-08-27 Phd Biosciences ( Formerly Nanometics Llc) Pyridoxamine for the treatment of sickle cell disease, thalassemia and related blood diseases

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150031068A1 (en) * 2012-03-19 2015-01-29 Lycera Corporation Methods and compositions for detecting immune system activation
US20160199463A1 (en) * 2014-12-15 2016-07-14 The Johns Hopkins University Hdac2 defends vascular endothelium from injury

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006521349A (ja) 2003-03-27 2006-09-21 メディキュア インコーポレーテッド 狭心症を治療するための組成物
US20120157501A1 (en) 2004-10-20 2012-06-21 Vanderbilt University Isoketal scavengers and mitigation of disorders involving oxidative injury
US20100017971A1 (en) 2006-09-01 2010-01-28 Kao Corporation One-part hair dye composition
US20100172971A1 (en) 2006-11-13 2010-07-08 Mccarty Mark Fredrick Compositions for Inhibiting NADPH Oxidase Activity
US20120015501A1 (en) 2010-07-14 2012-01-19 Chang-Ching Tu Silicon Surface Modification for the Electrochemical Synthesis of Silicon Particles in Suspension
JP2014524918A (ja) 2011-07-12 2014-09-25 ヴァンダービルト ユニバーシティー ガンマ−ケトアルデヒド捕捉剤による炎症および高血圧の治療方法
WO2015127163A1 (en) 2014-02-20 2015-08-27 Phd Biosciences ( Formerly Nanometics Llc) Pyridoxamine for the treatment of sickle cell disease, thalassemia and related blood diseases

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Antioxid Redox Signal，2013年，18(14)，1789-1796
Pulmonary Circulation，2011年，1(1)，72-83

Also Published As

Publication number Publication date
EP3541185A4 (en) 2020-06-24
EP3541185B1 (en) 2024-04-24
EP4385576A2 (en) 2024-06-19
PL3541185T3 (pl) 2024-08-12
WO2018093936A1 (en) 2018-05-24
CN110177463B (zh) 2022-03-08
EP3541185A1 (en) 2019-09-25
AU2017362328B2 (en) 2022-03-31
HUE067036T2 (hu) 2024-09-28
CN110177463A (zh) 2019-08-27
US20190314302A1 (en) 2019-10-17
ES2981715T3 (es) 2024-10-10
EP3541185C0 (en) 2024-04-24
AU2017362328A1 (en) 2019-06-27
JP2019536778A (ja) 2019-12-19
US20250381155A1 (en) 2025-12-18
EP4385576A3 (en) 2024-09-04

Similar Documents

Publication Publication Date Title
US20250381155A1 (en) Use of 2-hydroxybenzylamine in the treatment and prevention of pulmonary hypertension
JP6046702B2 (ja) 脳腫瘍の処置用のｃｓｆ−１ｒ阻害剤
US20210283108A1 (en) Method for treating neurodegenerative diseases
US11707472B2 (en) Compositions for the treatment of fibrosis
Kong et al. Effects of gestational isoflurane exposure on postnatal memory and learning in rats
US20130172414A1 (en) Pharmaceutical composition comprising levocarnitine and dobesilate
US6165515A (en) Method for treatment of osteoporosis
EP2862572B1 (en) Prophylactic and/or therapeutic agent for mild cognitive impairment
JP2020029457A (ja) 神経新生を促進する医薬組成物及びオニノヤガラ抽出物またはアデノシン類似物を利用して神経新生を促進する方法
US20180344694A1 (en) Use of indole compounds to stimulate the immune system
Montiel et al. Modulation of the autophagy‐lysosomal pathway and endoplasmic reticulum stress by ketone bodies in experimental models of stroke
KR102011105B1 (ko) 고시폴 및 펜포르민을 유효성분으로 포함하는 췌장암 예방 및 치료용 약학적 조성물
Zhang et al. Ginsenoside Rg1 improves hypoxia-induced pulmonary vascular endothelial dysfunction through TXNIP/NLRP3 pathway-modulated mitophagy
CN103169694B (zh) 正丁烯基苯酞在制造用于治疗肝损伤和改善肝功能的药物中的用途及药物组合物
WO2012151541A1 (en) Csf-1r inhibitors for treatment of brain tumors
HK40107155A (en) Use of 2-hydroxybenzylamine in the treatment and prevention of pulmonary hypertension
CN118892485A (zh) 凡德他尼及其药学上可接受的盐与硝苯地平及其药学上可接受的盐联合制备治疗癌症和长q-t间期综合症的药物中的用途
US8729026B2 (en) Method for inhibiting autophagy of motor neurons
HK40006700B (en) Use of 2-hydroxybenzylamine in the treatment and prevention of pulmonary hypertension
HK40006700A (en) Use of 2-hydroxybenzylamine in the treatment and prevention of pulmonary hypertension
KR102336691B1 (ko) 다이설피람 및 시스플라틴을 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물
CN103908567B (zh) 一种用于治疗糖尿病痛性神经病变的复方制剂及其应用
US20220162240A1 (en) Mitochondria-targeted isoketal/isolevuglandin scavengers
CN107595875B (zh) 含有丁苯酞的组合物及其在治疗脑血管病药物中的应用
KR102836097B1 (ko) 비알코올성 지방간 질환의 예방 또는 치료용 조성물

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201116

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201116

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210831

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210831

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211125

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220127

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220228

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220726

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221024

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221223

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230124

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230509

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230801

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20230801

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231003

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231031

R150 Certificate of patent or registration of utility model

Ref document number: 7383285

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150